The biotech sector has been one of the favorite sectors among hundreds of thousands of investors for many years now and for good reason. The second has grown enormously over the course of the past decades and there have been some path-breaking milestones as well. If you are currently looking into the possibility of investing in biotech stocks then you could take a look at these three stocks.
1. Biotech Stocks To Watch in September: ALX Oncology (NASDAQ:ALXO)
This is one of the innovative biotech companies to have managed to find a way to target the CD47 protein. Currently, it is regarded as one of the newest methods by way of which cancer can be fought since CD47 often makes it difficult to detect cancer.
The company is currently working on a way so that the signal can be blocked. The company currently has one medicine, named evorpacept, in its pipeline at this point in time and is looking into the possibility of starting a range of trials. It should be noted that there are other companies in this niche as well, who are also working on similar products. AXL Oncology is looking to target blood cancers and also work on tumors.
2. Biotech Stocks To Watch in September: Vertex Pharmaceuticals (NASDAQ:VRTX)
On the other hand, if you are on the lookout for a company with more pedigree but with innovative products in its pipeline then it might be a good time to look into Vertex Pharmaceuticals.
The company is mainly involved in treating cystic fibrosis and the management has stated that its product treats around 50% of the total 83000 patients of that condition in Europe, the United States, Australia, and Canada. Last April, the company picked up a 60% stake in gene-editing therapy from CRISPR Pharmaceuticals for $900 million and has managed to open up another frontier for growth.
3. Biotech Stocks To Watch in September: Beam Therapeutics (NASDAQ:BEAM)
Staying on the gene-editing theme, it could be a good move for investors to keep an eye on Beam Therapeutics as well. The company is trying to bring an innovative way of doing things as far as gene editing is concerned. Beam uses to base the method of base editing instead of CRISPR Cas9, a method that actually led to the creators winning the Nobel Prize in Chemistry.
The company also noted that it is hoping to send in its New Drug Application for its sickle cell disease treatment at some point in December. Up until then, it could be a stock to be watched.